Literature DB >> 16487850

A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes.

Sunil V Rao1, Kristi O'Grady, Karen S Pieper, Christopher B Granger, L Kristin Newby, Kenneth W Mahaffey, David J Moliterno, A Michael Lincoff, Paul W Armstrong, Frans Van de Werf, Robert M Califf, Robert A Harrington.   

Abstract

OBJECTIVES: The goal of this study was to determine the association between Thrombolysis In Myocardial Infarction (TIMI) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) bleeding and clinical outcomes.
BACKGROUND: There are limited data on the relative utility of either scale at predicting clinical outcomes in patients with non-ST-segment elevation acute coronary syndromes (ACS).
METHODS: Pooled data from two randomized trials of patients with ACS (n = 15,454) were analyzed to determine the association between TIMI and GUSTO bleeding and 30-day and 6-month death/myocardial infarction (MI) using Cox proportional hazards modeling that included bleeding as a time-dependent covariate.
RESULTS: There was a stepwise increase in the adjusted hazard of 30-day death/MI with worsening GUSTO bleeding (hazard ratio [95% confidence interval], GUSTO mild 1.20 [1.05 to 1.37]; moderate 3.28 [2.88 to 3.73]; severe 5.57 [4.33 to 7.17]), and an increased risk with all three levels of TIMI bleeding (TIMI minimal 1.84 [1.63 to 2.08]; TIMI minor 1.64 [1.31 to 2.04]; major 1.45 [1.23 to 1.70]). When both bleeding scales were included in the same model, the risk with GUSTO bleeding persisted; however, the association between TIMI bleeding and outcome was no longer significant.
CONCLUSIONS: Both scales identify ACS patients with bleeding complications at risk for adverse outcomes. In a model that included both definitions, the risk with GUSTO bleeding persisted while the risk with TIMI bleeding did not. This suggests that bleeding assessed with clinical criteria is more important than that assessed by laboratory criteria in terms of outcomes. Future clinical trials should consider using a combination of the GUSTO bleeding scale and the need for transfusion to assess bleeding complications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487850     DOI: 10.1016/j.jacc.2005.09.060

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  52 in total

1.  Acute coronary syndromes: Antithrombotics in ACS--moving beyond unfractionated heparin.

Authors:  Usman Baber; Roxana Mehran
Journal:  Nat Rev Cardiol       Date:  2011-09-27       Impact factor: 32.419

2.  'Ins' and 'outs' of triple therapy: Optimal antiplatelet therapy in patients on chronic oral anticoagulation who need coronary stenting.

Authors:  W Dewilde; F W A Verheugt; N Breet; J J Koolen; J M Ten Berg
Journal:  Neth Heart J       Date:  2010-09       Impact factor: 2.380

3.  Management of patients with acute coronary syndromes in real-world practice in Italy: an outcome research study focused on the use of ANTithRombotic Agents: the MANTRA registry.

Authors:  Gianni Casella; Giuseppe Di Pasquale; Luigi Oltrona Visconti; Maria Giovanna Pallotti; Donata Lucci; Pasquale Caldarola; Marino Scherillo; Aldo P Maggioni
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-03

4.  The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study.

Authors:  Brian O'Neill; Vikas Singh; Annapoorna Kini; Roxana Mehran; Evan Jacobs; David Knopf; Carlos E Alfonso; Claudia A Martinez; Pedro Martinezclark; William O'Neill; Alan W Heldman; Jennifer Yu; Usman Baber; Jason C Kovacic; George Dangas; Samin Sharma; Samantha Sartori; Mauricio G Cohen
Journal:  Catheter Cardiovasc Interv       Date:  2013-03-25       Impact factor: 2.692

5.  Severe spontaneous epistaxis: retrospective study in a tertiary ENT centre.

Authors:  Eline Marin; Jean-Baptiste Watelet; Philippe Gevaert; Thibaut Van Zele
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-19       Impact factor: 2.503

Review 6.  Clinical review: bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management.

Authors:  Magdalena Doktorova; Zuzana Motovska
Journal:  Crit Care       Date:  2013-09-27       Impact factor: 9.097

7.  Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil.

Authors:  Renato D Lopes; Richard C Becker; L Kristin Newby; Eric D Peterson; Elaine M Hylek; Robert Giugliano; Christopher B Granger; Kenneth W Mahaffey; Antonio C Carvalho; Otavio Berwanger; Roberto R Giraldez; Gilson Soares Feitosa-Filho; Marcia M Barbosa; Maria da Consolacao V Moreira; Renato A K Kalil; Marildes Freitas; Joao Carlos de Campos Guerra; Marcio Vinicius Lins Barros; Thiago da Rocha Rodrigues; Antonio C Lopes; David A Garcia
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

8.  Outcomes After Transcatheter Mitral Valve Repair in Patients With Renal Disease.

Authors:  Binita Shah; Pedro A Villablanca; Sreekanth Vemulapalli; Pratik Manandhar; Nicholas S Amoroso; Muhamed Saric; Cezar Staniloae; Mathew R Williams
Journal:  Circ Cardiovasc Interv       Date:  2019-02       Impact factor: 6.546

Review 9.  Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care.

Authors:  Marc Cohen
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

10.  Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy.

Authors:  Guido Parodi; Giuseppe De Luca; Guia Moschi; Benedetta Bellandi; Renato Valenti; Angela Migliorini; Nazario Carrabba; David Antoniucci
Journal:  J Thromb Thrombolysis       Date:  2010-11       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.